Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Lupin Limited
  6. News
  7. Summary
    500257   INE326A01037

LUPIN LIMITED

(500257)
  Report
End-of-day quote Bombay Stock Exchange  -  2022-12-08
750.90 INR   -0.48%
12:13pLupin : December 9, 2022 Lupin Launches Authorized Generic Version of PENNSAID« 2% w/w in the United States
PU
02:18aLupin Launches Generic Inflammatory Diseases Drug in US
MT
12/08Lupin : December 8, 2022 Lupin Appoints Spiro Gavaris as President of U.S. Generics Business
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Lupin Gets US FDA Nod for Overactive Bladder Drug

09/29/2022 | 06:49am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. 0.52% 2136 Delayed Quote.13.61%
LUPIN LIMITED -0.48% 750.9 End-of-day quote.-21.06%
All news about LUPIN LIMITED
12:13pLupin : December 9, 2022 Lupin Launches Authorized Generic Version of PENNSAID« 2% w/w in ..
PU
02:18aLupin Launches Generic Inflammatory Diseases Drug in US
MT
12/08Lupin : December 8, 2022 Lupin Appoints Spiro Gavaris as President of U.S. Generics Busine..
PU
12/08Lupin Appoints President for US Generics Business
MT
12/05Lupin : December 5, 2022 Lupin Launches Rufinamide Tablets USP in the United States
PU
12/05Lupin Launches Generic Seizures Drug in US
MT
12/05Lupin Launches Rufinamide Tablets USP in the United States
CI
11/29Lupin : November 29, 2022 Lupin Launches Formoterol Fumarate Inhalation Solution in the Un..
PU
11/29Lupin Launches Generic Drug for Breathing Difficulty
MT
11/29Lupin Launches Formoterol Fumarate Inhalation Solution in the United States
CI
More news
Analyst Recommendations on LUPIN LIMITED
More recommendations
Financials
Sales 2023 165 B 2 001 M 2 001 M
Net income 2023 6 625 M 80,3 M 80,3 M
Net Debt 2023 25 002 M 303 M 303 M
P/E ratio 2023 50,8x
Yield 2023 0,62%
Capitalization 341 B 4 141 M 4 141 M
EV / Sales 2023 2,22x
EV / Sales 2024 1,93x
Nbr of Employees 19 789
Free-Float 52,7%
Chart LUPIN LIMITED
Duration : Period :
Lupin Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LUPIN LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 37
Last Close Price 750,90 INR
Average target price 737,59 INR
Spread / Average Target -1,77%
EPS Revisions
Managers and Directors
Vinita D. Gupta Chief Executive Officer & Executive Director
Ramesh Swaminathan Global CFO & Executive Director
Manju Deshbandhu Gupta Non-Executive Chairman
Rajvardhan V. Satam Secretary & Compliance Officer
Johnny Mikell President-Global Quality & Compliance
Sector and Competitors
1st jan.Capi. (M$)
LUPIN LIMITED-21.06%4 169
JOHNSON & JOHNSON2.73%463 286
ELI LILLY AND COMPANY34.60%353 267
ABBVIE INC.20.43%293 450
PFIZER, INC.-12.31%290 657
NOVO NORDISK A/S22.08%287 434